Back
8-K ↗CT.gov ↗8-K ↗CT.gov ↗CT.gov ↗CT.gov ↗8-K ↗
MDGL
Madrigal Pharmaceuticals, Inc.
Madrigal Pharmaceuticals develops treatments for metabolic dysfunction-associated steatohepatitis (MASH), a liver disease characterized by fat accumulation and fibrosis. The company has one approved product, Rezdiffra, currently marketed in the United States and European Union for MASH patients with moderate to advanced liver fibrosis, with ongoing work to secure full regulatory approval and expand its use to a broader patient population.
$517.39+54.95%1Y
MDGL · daily close · illustrative · 0 catalysts marked
Pipeline
Phase 3NASH - Nonalcoholic Steatohepatitis
Phase 2MASH - Metabolic Dysfunction-Associated Steatohepatitis
Phase 3Non-Alcoholic Fatty Liver Disease
Phase 3NASH
Phase 3Cirrhosis, Liver
UnknownMASH
Unknowncompensated MASH cirrhosis (F4c)
UnknownDrug-drug interaction study
Catalyst Calendar
Q4
Readoutervogastat
“ervogastat/resmetirom drug-drug interaction study on track to initiate in 4Q26”
DEC
ReadoutResmetirom
“A Randomized Double-blind Placebo-controlled Phase 3 Study to Evaluate the Effect of Resmetirom on Liver-related Outcomes in Patients With Well-compensated (Child-Pugh A) Non-alcoholic Steatohepatitis (NASH) Cirrhosis (MAESTRO-NASH-OUTCOMES) — primary completion 2026-12”
2027
ReadoutResmetirom
“Baseline characteristics of patients from the OLE F4c cohort are similar to patients enrolled in the ongoing MAESTRO-NASH OUTCOMES trial which is expected to read out topline data in 2027.”
MAR
ReadoutResmetirom
“A 52-Week, Phase 3, Open-Label Extension Study, With a Double-blind Lead-in, to Evaluate Safety and Biomarkers of Resmetirom (MGL-3196) in Patients With Non-alcoholic Fatty Liver Disease (NAFLD), MAESTRO-NAFLD-Open-Label-Extension (MAESTRO-NAFLD-OLE) — primary completion 2027-03”
JAN
ReadoutMGL-3196
“A Phase 3, Multinational, Double-Blind, Randomized, Placebo-Controlled Study of MGL-3196 (Resmetirom) in Patients With Non-Alcoholic Steatohepatitis (NASH) and Fibrosis to Resolve NASH and Reduce Progression to Cirrhosis and/or Hepatic Decompensation — primary completion 2028-01”
AUG
ReadoutResmetirom
“Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate MGL-3196 (Resmetirom) in Patients With MASH Who Have Undergone Liver Transplant for MASH Cirrhosis or Other Etiologies — primary completion 2028-08”
Past (1)
MAY–MAY
Conf.Resmetirom
“Madrigal will present 8 abstracts at the European Association for the Study of Liver (EASL) Congress, taking place May 27-30, 2026, in Barcelona, Spain.”